<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of acute exacerbations of multiple sclerosis in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of acute exacerbations of multiple sclerosis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of acute exacerbations of multiple sclerosis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Olek, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Howard, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system that is a leading cause of disability in young adults.</p><p>Despite dramatic advances in the clinical assessment of MS due to the widespread availability of brain and spine magnetic resonance imaging, our understanding of the basic etiology of the disease remains limited. Full control of the disease and the repair of damaged myelin are key objectives for current and future investigators.</p><p>The treatment of acute exacerbations (also known as attacks or relapses) of MS is reviewed here. Other aspects of MS treatment are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults"</a>.)</p><p class="headingAnchor" id="H4238251380"><span class="h1">DEFINITION AND TERMINOLOGY</span><span class="headingEndMark"> — </span>An MS exacerbation or relapse is defined as a monophasic clinical episode with patient-reported symptoms and objective findings typical of MS, reflecting a focal or multifocal inflammatory demyelinating event in the central nervous system, developing acutely or subacutely, with a duration of at least 24 hours, with or without recovery, and in the absence of fever or infection [<a href="#rid1">1</a>]. </p><p>MS exacerbation, relapse, flare, and attack are synonyms [<a href="#rid1">1</a>]. The term "clinically isolated syndrome" (CIS) is also synonymous when used to denote the first clinical episode of MS; a CIS resembles a typical MS relapse but occurs in a patient not known to have MS. The term "relapse" is most often used for subsequent clinical attacks in a patient already diagnosed with MS. Since relapses may be multifocal or have a fluctuating onset and course, a period of clinical stability or improvement lasting at least 30 days is required to distinguish separate relapses [<a href="#rid2">2</a>]. </p><p class="headingAnchor" id="H2364623257"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H4180982523"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Relapses in MS are highly variable and may include one or multiple neurologic deficits involving sensory disturbance, motor weakness, visual disturbance, imbalance, fatigue, or cognitive difficulty [<a href="#rid2">2</a>]. Common presentations include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral optic neuritis, manifesting with painful, monocular visual loss consisting of visual blurring or scotoma</p><p class="bulletIndent1"><span class="glyph">●</span>Painless diplopia due to internuclear ophthalmoplegia (occasionally bilateral) or, less commonly, a sixth nerve palsy</p><p class="bulletIndent1"><span class="glyph">●</span>Brainstem or cerebellar syndrome, such as diplopia described above, ataxia with gaze-evoked nystagmus, vertigo, unilateral facial numbness, or paroxysmal episodes of dysarthria or vertigo</p><p class="bulletIndent1"><span class="glyph">●</span>Partial transverse myelitis, usually with predominant sensory symptoms, including a partial Brown-Sequard syndrome; other manifestations can include sphincter symptoms, with bladder involvement (eg urge incontinence) more common than bowel, and erectile dysfunction</p><p></p><p>Symptoms usually develop over the course of hours to days and then gradually remit (even if untreated) over the ensuing weeks to months, though remission may not be complete. </p><p class="headingAnchor" id="H1886918360"><span class="h2">Assessment and diagnosis</span><span class="headingEndMark"> — </span>Patients with a suspected MS relapse should be evaluated for fever and infection. A complete neurologic history and examination is necessary to assess for changes in cognition, vision (including visual acuity, color vision, and eye movements), strength, sensation, coordination, and gait [<a href="#rid3">3</a>]. Findings should be compared with the baseline from prior neurologic evaluations to determine if there is are changes consistent with an MS relapse. </p><p>In patients with MS, the diagnosis of a relapse is determined on clinical grounds based upon the symptoms and neurologic examination. An MRI is not obligatory if the clinical suspicion for an MS relapse is high or if the relapse is mild (eg, sensory only). If an MRI of the brain and/or spinal cord is obtained at the time of a relapse, it will often show a corresponding new lesion that enhances with the administration of gadolinium  (<a class="graphic graphic_diagnosticimage graphicRef130657" href="/z/d/graphic/130657.html" rel="external">image 1</a>). An MRI can definitively document that the patient is having a relapse and distinguish an MS attack from a "pseudorelapse," the temporary worsening of existing MS symptoms caused by increased body temperature, underlying infection, metabolic disturbance, or medical illness.</p><p class="headingAnchor" id="H3025189770"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Demonstration of an enhancing lesion in the brain or spinal cord that correlates with new or worsening MS symptoms can help distinguish an MS attack from a "pseudorelapse," the temporary worsening of existing MS symptoms caused by increased body temperature (due to infection, heat exposure, or exercise), underlying infection (eg, urinary tract or upper respiratory infection), metabolic disturbance, or medical illness. </p><p>In addition to pseudorelapse, an attack should be distinguished from alternative conditions including transient paroxysmal symptoms (eg, Lhermitte phenomenon, tonic spams, trigeminal neuralgia), day-to-day fluctuations, functional neurologic symptoms, and neurologic disorders other than MS [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/1689.html" rel="external">"Manifestations of multiple sclerosis in adults", section on 'Paroxysmal symptoms'</a>.)</p><p class="headingAnchor" id="H3630334876"><span class="h1">APPROACH TO TREATMENT</span></p><p class="headingAnchor" id="H2"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Indications for treatment of an acute relapse (MS exacerbation, attack) in patients with MS include functionally disabling symptoms with objective evidence of neurologic impairment such as loss of vision, diplopia, weakness, and/or cerebellar symptoms. Mild sensory attacks may not require treatment, although symptomatic relief with analgesics and glucocorticoid treatment is sometimes necessary because of patient discomfort (eg, due to paresthesia).</p><p class="headingAnchor" id="H2350820774"><span class="h2">Goals of treatment</span><span class="headingEndMark"> — </span>The main goal of treatment is to speed recovery time from the attack. However, acute treatment has no apparent benefit for improving long-term disability or for reducing the risk of subsequent attacks [<a href="#rid4">4</a>].</p><p>MS relapses may lead to residual, permanent disability [<a href="#rid5">5</a>]. Patients with active MS who manifest disease activity by either clinical relapses or recent magnetic resonance imaging (MRI) lesions (and/or new or unequivocally enlarging lesions) should be offered treatment with disease-modifying therapy. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/128298.html" rel="external">"Treatment of primary progressive multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/129091.html" rel="external">"Overview of disease-modifying therapies for multiple sclerosis"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Initial therapy with glucocorticoids</span><span class="headingEndMark"> — </span>We recommend high-dose, short-term glucocorticoid therapy for patients with an acute MS exacerbation that results in neurologic symptoms and increased disability or impairments in vision, strength, cerebellar function, or significant sensory disturbances. Before starting therapy, acute infection (particularly of the urinary tract) should be ruled out, and any active infection should be treated, since glucocorticoids are immunosuppressive and may exacerbate infection. </p><p>Options for intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> or oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> are listed below. Where available, <a class="drug drug_general" data-topicid="8885" href="/z/d/drug information/8885.html" rel="external">corticotropin injection gel</a> is an alternative when glucocorticoids are not an option. (See <a class="local">'Alternative therapy with ACTH'</a> below.) </p><p class="headingAnchor" id="H1264955322"><span class="h3">Intravenous methylprednisolone</span><span class="headingEndMark"> — </span>Three- to seven-day courses of intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, 500 to 1000 mg daily, with or without a short <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> taper, are used most commonly [<a href="#rid6">6,7</a>]. Our preferred regimen is intravenous methylprednisolone 1000 mg daily for five days, though this may be truncated for minor relapses where patients have symptomatic relief with fewer than five treatments. </p><p class="headingAnchor" id="H1714385090"><span class="h3">Oral prednisone</span><span class="headingEndMark"> — </span>An alternative is a three- to seven-day course of oral <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, 1000 mg daily, or oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, 1250 mg daily, with or without a short taper. Our preferred regimen is oral methylprednisolone (1000 mg) without an oral taper. Oral dosing requires many tablets (eg, up to 31 tablets daily of methylprednisolone 32 mg tablets to reach a dose of approximately 1000 mg) but some patients prefer oral therapy rather than intravenous therapy, as the latter requires an intravenous line, sitting still for a few hours while the medication is infused, and potentially being admitted to the hospital.</p><p>The bioavailability of oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (1250 mg) appears to be equal to that of intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (1000 mg) [<a href="#rid8">8</a>]. However, one study found a higher peak concentration after a single dose of intravenous methylprednisolone than after a single dose of the oral formulation [<a href="#rid8">8</a>]. The clinical significance of the peak concentration for efficacy is unknown.</p><p class="headingAnchor" id="H1952669360"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Short-term high-dose glucocorticoid therapy is associated with relatively few side effects in most patients, although mental status changes, increased susceptibility to infection, and gastric disturbance are potential complications. Psychiatric adverse effects can include increased depressive, manic, and hypomanic symptoms [<a href="#rid9">9</a>]. To mitigate these adverse effects, strategies include the prophylactic use of a proton pump inhibitor in the morning and/or low-dose <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a> at night while on glucocorticoid treatment. Patients with diabetes mellitus may need to be hospitalized to monitor glucose levels. </p><p>An increased incidence of fractures has been reported in patients undergoing repeated glucocorticoid therapy; baseline and yearly bone density scans are recommended for these individuals. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'General measures'</a>.)</p><p class="headingAnchor" id="H722252225"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The evidence for the benefit of glucocorticoid treatment of MS relapses is supported by several randomized controlled trials. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Placebo controlled trials</strong> – A systematic review and meta-analysis published in 2000 identified six randomized controlled trials comparing <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> or adrenocorticotropic hormone (ACTH) with placebo in a total of 377 patients with acute exacerbations of MS [<a href="#rid10">10</a>]. Methylprednisolone was tested in four trials with 140 patients; it was administered orally in one trial (500 mg daily for five days followed by a 10-day taper), and intravenously in three trials (500 mg daily or 1000 mg daily for five days in two trials, and 15 mg/kg daily for three days in the third). Compared with placebo, patients treated with ACTH or methylprednisolone had a significant reduction in the risk of either worsening or not improving within five weeks from randomization (odds ratio [OR] 0.37, 95% CI 0.24-0.57). In a subgroup analysis by drug, both methylprednisolone treatment and ACTH treatment reduced the risk of worsening or not improving within five weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral versus intravenous glucocorticoids</strong> – Small randomized trials comparing oral versus intravenous glucocorticoids for acute MS attacks have found no important differences in benefit [<a href="#rid11">11,12</a>]. In a double-blind non-inferiority randomized trial (COPOUSEP) that enrolled 199 adults with relapsing-remitting MS who had a relapse within the previous 15 days, there was no significant difference between treatment with oral or intravenous high-dose <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (1000 mg once a day for three days) for the outcome of improvement in disability scores by day 28 [<a href="#rid13">13</a>]. In addition, there was no significant difference between treatment groups in the rate of recurrent relapses at six months.</p><p></p><p class="bulletIndent1">Another randomized trial of 80 patients with acute MS relapse compared oral <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (48 mg daily for seven days, followed by 24 mg daily for seven days, and finally by 12 mg daily for seven days) versus intravenous methylprednisolone (1000 mg daily for three days) [<a href="#rid14">14</a>]. There was no statistical difference between the treatment groups for any of the outcome measures. In an assessor-blinded trial, 40 patients with an acute MS attack were randomly assigned to treatment with either oral or intravenous high-dose methylprednisolone at 1000 mg daily for five days [<a href="#rid15">15</a>]. At one week, both groups showed a similar reduction of gadolinium-enhancing lesions on brain MRI. At four weeks, both groups showed a similar improvement in clinical status.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with optic neuritis</strong> – Though previous studies suggested oral glucocorticoids were less effective than intravenous glucocorticoids for patients with optic neuritis, a randomized trial of 55 subjects found that oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (1250 mg) was equivalent to intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> sodium succinate (1000 mg) for patients with optic neuritis [<a href="#rid16">16</a>]. However, some experts continue to recommend intravenous rather than oral glucocorticoids for patients with acute optic neuritis. (See  <a class="medical medical_review" href="/z/d/html/5252.html" rel="external">"Optic neuritis: Prognosis and treatment"</a>.)</p><p></p><p class="headingAnchor" id="H3564119753"><span class="h2">Alternative therapy with ACTH</span><span class="headingEndMark"> — </span>For patients who cannot tolerate high-dose glucocorticoids or have poor venous access or who prefer self-injection, repository <a class="drug drug_general" data-topicid="8885" href="/z/d/drug information/8885.html" rel="external">corticotropin injection gel</a>, a purified form of bovine or porcine adrenocorticotropic hormone (ACTH), is available in the United States (as HP Acthar Gel) and several other countries. It is administered by intramuscular (IM) or subcutaneous (SQ) injection. Various dosing schedules have been used in trials and in clinical practice for adults with acute MS exacerbations, generally starting corticotropin at 80 to 120 units daily by IM or SQ injection for one week followed, or not followed, by a taper [<a href="#rid17">17</a>]. Our preferred regimen is corticotropin injection gel 80 units daily for one week followed by a tapering schedule over a second week (eg, total dosage: 80 units for seven days, 40 units for four days, and 20 units for three days). The IM and SQ administration of corticotropin appear to be bioequivalent [<a href="#rid18">18</a>]. </p><p>The benefit of ACTH is probably similar to that of intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (see <a class="local">'Efficacy'</a> above). However, <a class="drug drug_general" data-topicid="8885" href="/z/d/drug information/8885.html" rel="external">corticotropin injection gel</a> is much more expensive than equivalent doses of methylprednisolone or <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>. </p><p class="headingAnchor" id="H762122468"><span class="h2">Assessing response to initial therapy</span><span class="headingEndMark"> — </span>While there are no clear guidelines or standards for determining the response to relapse treatment, one approach is to assess recovery in terms of how much the patient has returned to their baseline before the relapse. Residual disability that prevents a return to pre-relapse level of function may be considered to be a poor response. </p><p>The degree of symptom resolution and recovery may vary according to the timing of post-relapse functional assessment [<a href="#rid19">19</a>]. Patients experiencing day-to-day improvement during a five-day course of high-dose glucocorticoid treatment may be expected to continue to improve in the following days to weeks after treatment. In contrast, patients who have disabling deficits with little or no objective improvement or with worsening after three to seven days may benefit from another treatment course, as discussed below. </p><p class="headingAnchor" id="H6"><span class="h2">Treatment of refractory relapse</span><span class="headingEndMark"> — </span>For patients with a poor response to initial treatment, we suggest plasma exchange (PLEX) (see <a class="local">'Plasma exchange'</a> below). Other options for a second treatment course after a poor response to initial with high-dose glucocorticoid therapy include ACTH (see <a class="local">'Alternative therapy with ACTH'</a> above), a second cycle of high-dose glucocorticoid therapy, or immunoadsorption (see <a class="local">'Immunoadsorption'</a> below) where available. Intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> has been tried, but one small randomized trial found no benefit [<a href="#rid20">20</a>]. </p><p class="headingAnchor" id="H3543528203"><span class="h3">Plasma exchange</span><span class="headingEndMark"> — </span>We suggest treatment with PLEX for patients with acute, severe neurologic deficits caused by MS attacks who have a poor response to treatment with high-dose glucocorticoids [<a href="#rid21">21,22</a>]. One author (JH) uses PLEX particularly for patients with large, tumefactive lesions causing severe deficits such as hemiplegia, paraplegia, quadriplegia, coma, aphasia, or acute severe cognitive dysfunction, and for patients with optic neuritis and severe visual impairment (acuity worse than 20/400) [<a href="#rid23">23</a>]. Such relapses are uncommon but not extraordinarily rare.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – PLEX is administered daily or every other day for a total of three to seven treatments (eg, seven treatments given every two days over 14 days, or daily treatment for five to seven days). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – In experienced centers, complications from PLEX are uncommon and generally mild; rarely patients may experience potentially severe complications such as anaphylaxis, catheter infection and thrombosis, bleeding, hypotension, cardiac arrhythmias, and a toxic reaction to the citrate used in the procedure. (See  <a class="medical medical_review" href="/z/d/html/7942.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – PLEX may be beneficial in patients with acute central nervous system (CNS) inflammatory demyelinating disease who do not respond to glucocorticoid therapy. In the only formally reported clinical trial, 22 patients with CNS demyelinating disease (12 with MS) were randomly assigned to either active PLEX or sham treatment, with a total of seven treatments, given every two days over 14 days [<a href="#rid24">24</a>]. Moderate or greater improvement in neurologic disability occurred during 8 of 19 (42 percent) courses of active treatment compared with 1 of 17 (6 percent) courses of sham treatment. Improvement occurred early in the course of treatment and was sustained on follow-up. However, four of the patients who responded to the active treatment experienced new attacks of demyelination during six months of follow-up. In an earlier randomized controlled trial of 116 patients with MS, a subgroup analysis of patients with relapsing forms of MS showed that plasma exchange led to faster improvement in disease exacerbations than sham plasma exchange [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">Based mainly upon the results of this trial, guidelines from the American Academy of Neurology state that plasmapheresis should be considered for the adjunctive treatment of exacerbations in patients with relapsing forms of MS [<a href="#rid23">23</a>]. Nonrandomized studies have suggested benefit as well. In a series of 90 patients with MS or a clinically isolated syndrome suggestive of MS who had acute relapses, a clinical response to PLEX was observed in 72 percent [<a href="#rid26">26</a>]. The presence of gadolinium-enhancing lesions on MRI before treatment best predicted response to treatment [<a href="#rid26">26</a>]. </p><p></p><p class="headingAnchor" id="H2688927690"><span class="h3">Immunoadsorption</span><span class="headingEndMark"> — </span>Immunoadsorption is a method of apheresis that removes circulating autoantibodies. In contrast to PLEX, which nonselectively removes plasma proteins from circulation, immunoadsorption selectively binds and removes immunoglobulins. Treatment requires a large bore intravenous catheter, similar to PLEX. High cost and restricted availability limit the use of this therapy. </p><p>Evidence of efficacy is limited to lower quality studies. An unblinded controlled trial enrolled 61 patients with a glucocorticoid-refractory MS relapse and randomly assigned them to treatment with immunoadsorption or PLEX [<a href="#rid27">27</a>]. Both groups showed improvement as measured by the Multiple Sclerosis Functional Composite (MSFC) score, a scale evaluating the degree of impairment in MS; patients assigned to immunoadsorption showed a larger improvement in MSFC compared with patients assigned to PLEX at four weeks after apheresis but not at earlier time points. The results of two retrospective studies also suggested benefit with immunoadsorption for patients with MS relapses unresponsive to glucocorticoid treatment [<a href="#rid28">28,29</a>]. </p><p>In a retrospective study of 69 patients with early active demyelinating MS, as demonstrated by brain biopsy, patients with T cell-mediated or T cell plus antibody and complement-mediated autoimmune pathology were more likely to benefit from apheresis with plasma exchange or immunoadsorption than those with primary oligodendrocyte degeneration pathology [<a href="#rid30">30</a>]. These results suggest that pathophysiologic differences in MS lesions play a role in the response to apheresis, but this finding needs confirmation in larger prospective studies and at this point is primarily important for these insights rather than as a practical approach to treatment.</p><p class="headingAnchor" id="H4249291509"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117065.html" rel="external">"Society guideline links: Multiple sclerosis and related disorders"</a>.)</p><p class="headingAnchor" id="H18729495"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15821.html" rel="external">"Patient education: Multiple sclerosis in adults (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions </strong>– An MS exacerbation or relapse is defined as a monophasic clinical episode with patient-reported symptoms and objective findings typical of MS, reflecting a focal or multifocal inflammatory demyelinating event in the central nervous system, developing acutely or subacutely, with a duration of at least 24 hours, with or without recovery, and in the absence of fever or infection. MS exacerbation, relapse, and attack are synonyms. (See <a class="local">'Definition and terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Relapses in MS are highly variable and may include one or multiple neurologic deficits involving sensory disturbance, motor weakness, visual disturbance (eg, monocular visual loss or diplopia), imbalance, fatigue, or cognitive difficulty. (See <a class="local">'Clinical features'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – In patients with MS, the diagnosis of a relapse is determined on clinical grounds based upon the symptoms and neurologic examination. An MRI is not obligatory if the clinical suspicion for an MS relapse is high or if the relapse is mild (eg, sensory only). However, demonstration of an enhancing lesion in the brain or spinal cord by MRI that correlates with new or worsening MS symptoms can help distinguish an MS attack from a "pseudorelapse," the temporary worsening of existing MS symptoms caused by increased body temperature, underlying infection, metabolic disturbance, or medical illness. (See <a class="local">'Assessment and diagnosis'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid treatment</strong> – For patients with an acute MS exacerbation (relapse, attack) that results in neurologic symptoms and increased disability or impairments in vision, strength, or cerebellar function, we recommend a short course of high-dose glucocorticoid therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The main goal of treatment is to speed recovery time from the MS attack. However, acute treatment has no apparent benefit for improving long-term disability or for reducing the risk of subsequent attacks. Our preferred regimen is intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 1000 mg daily for five days without an oral taper. However, the data suggest that high-dose oral glucocorticoid regimens are just as effective. Repository <a class="drug drug_general" data-topicid="8885" href="/z/d/drug information/8885.html" rel="external">corticotropin injection gel</a>, where available, is an alternative for patients with MS exacerbations who cannot tolerate high-dose glucocorticoids or have poor venous access or prefer self-injection. Infection must first be ruled out. (See <a class="local">'Initial therapy with glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poor response to glucocorticoid treatment</strong> – For patients with acute, severe neurologic deficits caused by MS who have a poor response to treatment with high-dose glucocorticoids, we suggest treatment with plasma exchange (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Treatment of refractory relapse'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of disease-modifying therapy</strong> – Patients with relapsing-remitting MS who have current disease activity manifested by clinical symptoms or MRI lesions should be offered disease-modifying therapy. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17:162.</a></li><li><a class="nounderline abstract_t">Galea I, Ward-Abel N, Heesen C. Relapse in multiple sclerosis. BMJ 2015; 350:h1765.</a></li><li><a class="nounderline abstract_t">Wang C, Ruiz A, Mao-Draayer Y. Assessment and Treatment Strategies for a Multiple Sclerosis Relapse. J Immunol Clin Res 2018; 5.</a></li><li><a class="nounderline abstract_t">Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000; 247:435.</a></li><li><a class="nounderline abstract_t">Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61:1528.</a></li><li><a class="nounderline abstract_t">Kupersmith MJ, Kaufman D, Paty DW, et al. Megadose corticosteroids in multiple sclerosis. Neurology 1994; 44:1.</a></li><li><a class="nounderline abstract_t">Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ 2006; 332:525.</a></li><li><a class="nounderline abstract_t">Morrow SA, Stoian CA, Dmitrovic J, et al. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 2004; 63:1079.</a></li><li><a class="nounderline abstract_t">Morrow SA, Barr J, Rosehart H, Ulch S. Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses. J Affect Disord 2015; 187:142.</a></li><li><a class="nounderline abstract_t">Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; :CD001331.</a></li><li><a class="nounderline abstract_t">Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012; 12:CD006921.</a></li><li><a class="nounderline abstract_t">Liu S, Liu X, Chen S, et al. Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials. PLoS One 2017; 12:e0188644.</a></li><li><a class="nounderline abstract_t">Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 2015; 386:974.</a></li><li><a class="nounderline abstract_t">Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349:902.</a></li><li><a class="nounderline abstract_t">Martinelli V, Rocca MA, Annovazzi P, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 2009; 73:1842.</a></li><li><a class="nounderline abstract_t">Morrow SA, Fraser JA, Day C, et al. Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial. JAMA Neurol 2018; 75:690.</a></li><li><a class="nounderline abstract_t">Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989; 39:969.</a></li><li><a class="nounderline abstract_t">Brod SA, Morales MM. Bio-equivalence of IM and SQ H.P. Acthar Gel. Biomed Pharmacother 2009; 63:251.</a></li><li><a class="nounderline abstract_t">Ross AP, Halper J, Harris CJ. Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective. Int J MS Care 2012; 14:148.</a></li><li><a class="nounderline abstract_t">Visser LH, Beekman R, Tijssen CC, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004; 10:89.</a></li><li><a class="nounderline abstract_t">Arrambide G, Iacobaeus E, Amato MP, et al. Aggressive multiple sclerosis (2): Treatment. Mult Scler 2020; 26:1352458520924595.</a></li><li><a class="nounderline abstract_t">Bevan C, Gelfand JM. Therapeutic management of severe relapses in multiple sclerosis. Curr Treat Options Neurol 2015; 17:345.</a></li><li><a class="nounderline abstract_t">Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 76:294.</a></li><li><a class="nounderline abstract_t">Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878.</a></li><li><a class="nounderline abstract_t">Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989; 39:1143.</a></li><li><a class="nounderline abstract_t">Ehler J, Koball S, Sauer M, et al. Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients. PLoS One 2015; 10:e0134583.</a></li><li><a class="nounderline abstract_t">Dorst J, Fangerau T, Taranu D, et al. Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial. EClinicalMedicine 2019; 16:98.</a></li><li><a class="nounderline abstract_t">Mauch E, Zwanzger J, Hettich R, et al. [Immunoadsorption for steroid-unresponsive multiple sclerosis-relapses: clinical data of 14 patients]. Nervenarzt 2011; 82:1590.</a></li><li><a class="nounderline abstract_t">Schimrigk S, Faiss J, Köhler W, et al. Escalation Therapy of Steroid Refractory Multiple Sclerosis Relapse with Tryptophan Immunoadsorption - Observational Multicenter Study with 147 Patients. Eur Neurol 2016; 75:300.</a></li><li><a class="nounderline abstract_t">Stork L, Ellenberger D, Beißbarth T, et al. Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis. JAMA Neurol 2018; 75:428.</a></li></ol></div><div id="topicVersionRevision">Topic 1698 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29275977" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25872511" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Relapse in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30417033" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Assessment and Treatment Strategies for a Multiple Sclerosis Relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10929272" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14663037" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of relapses on development of residual deficit in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8290041" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Megadose corticosteroids in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16513709" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnosis and treatment of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15452302" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26334182" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11034713" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235634" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29176905" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26135706" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9093250" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19949030" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507942" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2544829" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18848765" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bio-equivalence of IM and SQ H.P. Acthar Gel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24453746" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760960" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32530366" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Aggressive multiple sclerosis (2): Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25794777" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Therapeutic management of severe relapses in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21242498" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589540" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2549450" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26244762" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31832624" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21667161" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : [Immunoadsorption for steroid-unresponsive multiple sclerosis-relapses: clinical data of 14 patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27304890" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Escalation Therapy of Steroid Refractory Multiple Sclerosis Relapse with Tryptophan Immunoadsorption - Observational Multicenter Study with 147 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29404583" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
